Dr Christine Galustian

Christine is a PI and Non-clinical lead of the Prostate Cancer Immunotherapy group which holds a Centre grant from the Prostate Cancer Research Centre at King's. Christine has a team of 4 scientists that are developing novel immunotherapeutic agents for prostate cancer and are testing these compounds in-vitro and in pre-clinical models.

The group has a translational approach to guide novel immunotherapeutics from the lab to the patient, where Christine is linked to the clinical lead Professor Dasgupta, who is planning clinical trials on the therapeutics produced in the lab along with Dr Richard Smith who directs the chemical synthesis and development of therapeutics through his novel cytotopic technology